Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.36 |
| ▸ | HTR1D | P28221 | 3/20 | 0.35 |
| ▸ | HTR1B | P28222 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004366 | 0.95 | MTNR1A (0.39) | HTR1AMTNR1AMTNR1BHTR1DHTR1B | |
| SCHEMBL2004819 | 0.93 | PPARD (0.40) | HTR1AMTNR1AMTNR1BHTR1DHTR1B | |
| SCHEMBL2004872 | 0.88 | CYP1A2 (0.39) | HTR1AMTNR1AMTNR1BHTR1DHTR1B | |
| SCHEMBL2026488 | 0.84 | PPARA (0.35) | PPARDPPARAKDM4ETRPV3WNT1 | |
| SCHEMBL2004833 | 0.84 | CYP1A2 (0.43) | MTNR1AMTNR1BHTR2AKDM4EMAPT | |
| SCHEMBL4229896 | 0.82 | PPARD (0.39) | HTR1AMTNR1AMTNR1BHTR1DHTR1B | |
| SCHEMBL2004284 | 0.81 | KDM4E (0.51) | HTR1AMTNR1AMTNR1BHTR1DHTR1B | |
| SCHEMBL2006659 | 0.79 | PPARD (0.47) | HTR1AMTNR1AMTNR1BHTR1DHTR1B | |
| SCHEMBL2004368 | 0.79 | APP (0.35) | MTNR1APPARDPPARAKDM4EMAPT | |
| SCHEMBL2008026 | 0.79 | PPARD (0.46) | HTR1ASLC6A4MTNR1AMTNR1BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | HTR1A 267/4885SLC6A4 486/4885MTNR1A 783/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | HTR1A 267/4885SLC6A4 486/4885MTNR1A 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.